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Abstract
Background: An association was previously established between facial nerve paralysis (Bell’s palsy) and intranasal
administration of an inactivated influenza virosome vaccine containing an enzymatically active Escherichia coli Heat Labile
Toxin (LT) adjuvant. The individual component(s) responsible for paralysis were not identified, and the vaccine was
withdrawn.
Methodology/Principal Findings: Subjects participating in two contemporaneous non-randomized Phase 1 clinical trials of
nasal subunit vaccines against Human Immunodeficiency Virus and tuberculosis, both of which employed an enzymatically
inactive non-toxic mutant LT adjuvant (LTK63), underwent active follow-up for adverse events using diary-cards and clinical
examination. Two healthy subjects experienced transient peripheral facial nerve palsies 44 and 60 days after passive nasal
instillation of LTK63, possibly a result of retrograde axonal transport after neuronal ganglioside binding or an inflammatory
immune response, but without exaggerated immune responses to LTK63.
Conclusions/Significance: While the unique anatomical predisposition of the facial nerve to compression suggests nasal
delivery of neuronal-binding LT–derived adjuvants is inadvisable, their continued investigation as topical or mucosal
adjuvants and antigens appears warranted on the basis of longstanding safety via oral, percutaneous, and other mucosal
routes.
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Introduction
Mucosal immunization via intranasal route has received much
attention in recent years [1] due to potential advantages of needle-
free delivery and enhanced mucosal immune responses against
infections such as influenza or Human Immunodeficiency Virus
(HIV), which can be enhanced by co-administration of effective
mucosal adjuvants such as mutants of Escherichia coli heat labile toxin
(LT) [2]. However, this immunization approach raised concerns
after a strong epidemiological association was reported [3] between
facial nerve paralysis (Bell’s Palsy) and intranasal administration of
inactivated influenza virosome vaccine ‘‘NasalFlu’’ containing an
enzymatically active mutant LT adjuvant [4]. Retrospective analysis
did not identify relative contributions of vaccine components [3],
and NasalFlu was withdrawn. We report two cases of transient Bell’s
Palsy following nasal administration of a genetically detoxified LT
adjuvant (LTK63) [2] during two Phase 1 vaccine trials.
Methods
Objectives and participants
The cases reported here occurred during two contemporaneous,
open-label, Phase 1 clinical vaccine trials of safety and immunoge-
nicity at the same clinical site (St George’s Vaccine Institute, London).
No formal sample size calculations were made, as is usual in this early
stage of evaluation. Full details of trials outcomes are in preparation
for publication. Briefly, nine BCG vaccine-naive healthy subjects
aged 18–45 were entered into a non-randomized Phase 1 trial of a
nasal Mycobacterium tuberculosis subunit vaccine [5] (full protocol
available on ClinicalTrials.gov NCT00440544: http://clinicaltrials.
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gov/ct2/show/NCT00440544, EudraCT: 2005-005983-10). The
first four subjects received two nasal immunizations (days 0 and 56)
with 100 mg Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein
alone, and the subsequent five subjects received two nasal
immunizations (days 0 and 56) of 100 mg Mycobacterium tuberculosis
Ag85B-ESAT6 fusion protein mixed with 30 mg LTK63. After the
event reported here the trial was terminated prior to recruitment of
subsequent planned groups.
In the contemporaneous trial, 30 healthy subjects aged 18–45
were entered into a non-randomized Phase 1 clinical trial of a nasal
HIV glycoprotein-140 subunit vaccine [6] (full protocol available on
ClinicalTrials.gov NCT00369031: http://clinicaltrials.gov/ct2/
show/NCT00369031, EudraCT: 2005-005140-81), and allocated
to one of three consecutively-recruited groups (10 per group) to
receive three intranasal immunisations (days 0, 28, and 56) with
either: 100 mg HIV glycoprotein-140 mixed with 30 mg LTK63,
100 mg HIV glycoprotein-140 alone, or 30 mg LTK63 alone. All
subjects received two intramuscular immunizations with 100 mg
HIV glycoprotein-140 mixed with MF59 adjuvant [7] on days 112
and 196. Following the case reported here 4 subjects in the group
receiving 30 mg LTK63 alone nasally underwent only one nasal
immunization, but did receive two intramuscular immunizations.
The subject reported here had no further immunizations after the
first nasal immunization with 30 mg LTK63 alone.
Collection, processing, and analysis of serum and nasal
lavage samples for immune responses to LTK63
Blood and nasal samples were obtained at pre-defined time
points before and after immunization. Blood was collected by
antecubital fossa venepuncture, serum separated and frozen at
220uC. Nasal lavage with 5 mL sterile water was performed via
urinary catheter placed the anterior nares bilaterally, and samples
frozen at 280uC. IgG and IgA antibodies to LTK63 were
detected by indirect ELISA [8], expressed in mg/mL using a
human immunoglobulin standard (NIBSC, UK).
Investigations for alternative causes of facial nerve
paralysis
Pre- and post-immunization serum or plasma samples were
retrospectively analysed for evidence of the most common
conditions associated with Bell’s palsy including serology/PCR/
antigen detection of infection with Human Immunodeficiency
Virus, Epstein-Barr Virus (EBV), Varicella zoster virus (VZV),
Borrelia burgdorferi, measles, mumps, Herpes simplex 1 and 2 (HSV)
and cytomegalovirus (CMV); or autoimmune diseases including
antinuclear antibodies (ANA), anti-neutrophil cytoplasmic anti-
bodies (ANCA) and Angiotensin Converting Enzyme (ACE) levels.
Both subjects declined radiological examinations.
Ethics
All subjects provided written informed consent before under-
going screening or participation in the trials, which were both
approved by St George’s Research Ethics Committee and UK
Medicines and Healthcare products Regulatory Agency. In
addition the two subjects reported here provided additional
written consent for publication of details which may include
identifying information.
Results
Case 1
A healthy 29 year old, white male enrolled into nasal
Mycobacterium tuberculosis subunit vaccine trial 2005-005983-10.
He reported an uncomplicated nasal procedure age 6, insertion of
tympanic membrane grommets in childhood, mild conjunctivitis
when pollen count high, mild itching after prolonged grass
contact, but no seasonal rhinitis, neurological disease, migraine or
regular medications. Screening HIV, hepatitis B and C serology,
hematology and biochemistry were negative or normal. Mantoux
test and ‘QuantiFERON-TB Gold’ (Cellestis, UK) were negative
for latent tuberculosis. Medical examination including ear, nose
and throat (ENT) and cranial nerves was normal apart from scar
on right tympanic membrane. Chest radiograph was normal. He
received 100 mg Mycobacterium tuberculosis Ag85B-ESAT6 fusion
protein and 30 mg LTK63, in 300 mL physiological buffer, by
passive instillation of drops divided equally between right and left
anterior nares. A diary was issued to record symptoms.
On day 1 he recorded mild malaise, ENT discomfort, and
cough. Examination on day 7 was normal. Between days 34–43 he
recorded mild itching of eyes and took loratidine. Examination on
day 43 was normal. Between days 45–48 he experienced mild
coryza and nasal discharge treated with acetaminophen. Exam-
ination on day 56 was normal, and he received second nasal
immunization with Ag85B-ESAT6 and LTK63 as before.
Between days 57–61 took loratidine for a sensation of fluid in
right ear. On day 58 he experienced a migraine-like visual aura
bilaterally, lasting 20 minutes. On day 60 he noticed mild right
sided post-auricular pain, followed by abnormality of taste,
worsening over day 61. On day 62 (5 days after second
immunization) he developed right-sided facial asymmetry and
increased tear production.
On examination on day 64 he was afebrile, cardiovascular,
respiratory, abdominal examination normal, no mastoid tender-
ness, rashes or peri-auricular vesicles. ENT normal except clear
fluid behind non-inflamed right tympanic membrane. Sense of
smell normal on testing. Cranial nerves 2–6 normal, corneal reflex
intact, pupils equal and responsive, fundoscopy normal. House-
Brackmann [9] grade V signs of right lower motor neurone facial
nerve palsy present, with inability to taste salt, sour, and bitter on
right anterior portion of tongue, and profuse tear production (seen
in 67% of Bell’s palsies [10] as orbicularis oculis dysfunction
prevents tear transport to lacrimal sac, without hypersecretion).
Marked Bell’s phenomenon (upward gaze upon attempting to
close affected eye) observed, confirming peripheral lesion [11].
Hearing and balance normal, Rinne’s normal, Weber localized to
right (seen in Bell’s palsy, also compatible with observed middle
ear fluid). Cranial nerves 9–12 normal. Sensation over head and
neck normal. He was prescribed prednisolone, omeprazole,
aciclovir (8 days), eye drops & patches according to UK guidance
[12]. Palsy was graded III on day 70, and II by day 78 without
increased tearing, and steroids discontinued. Symptoms of right
retro-auricular pain and abnormality of taste recurred between
days 87–89 (30–32 after second immunization) without facial
paralysis. He recommenced prednisolone and aciclovir for 11 and
7 days respectively. On day 91 examination was normal except
slight abnormality of taste. Examination on days 126 and 225
(168 days after second immunization) were normal.
There were no clinically significant abnormalities of hematology
and biochemistry throughout study. Screening and day 225
samples were tested for: HIV 1&2 antibody, p24 antigen
(negative); VZV (IgM negative, IgG positive, no rise in titer); B.
burgdorferi (IgG and IgM negative); measles, mumps (IgG positive,
no rise in titer); HSV 1 and 2 (IgG negative); CMV (IgG and IgM
negative); ANA, ANCA (negative). ACE 22 U/L day 56, and 16
day 91 (normal range 8–52). Anti-BV Nuclear Antigen positive on
screening and on day 225, no rise in titer; anti-EBV Early Antigen
IgG 52 at screening rising to 150 on day 225; anti-EBV Early
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Antigen IgM 23?5 (weak positive) at screening and 14?2 (negative)
on day 225. This pattern suggests possibility of EBV infection in
months before screening.
Case 2
A healthy 20 year old, white female enrolled into nasal HIV
glycoprotein-140 subunit vaccine trial 2005-005140-81. She gave
no history of neurological or otolaryngology disease, was taking no
regular medications except oral contraceptives. Screening HIV,
hepatitis B and C serology, plasma HIV nucleic acid, hematology
and biochemistry panels, blood and urine pregnancy tests were
negative or normal. Physical examination was normal including
ENT and cranial nerves. She received 30 mg of LTK63 (as a nasal
placebo) in 284 mL physiological buffer, by passive instillation of
drops divided equally between right and left anterior nares. A
symptoms diary was issued.
On days 2 and 3 she recorded mild malaise, nasal congestion
and headache, resolved with ibuprofen. Examination on day 3 was
normal. Between days 8–11 she reported mild headache, resolved
by stat acetaminophen and pseudoephedrine. On day 28 she was
afebrile, physical examination normal; hematology and biochem-
istry normal. Her scheduled second (and subsequently third)
immunization was cancelled due to Bell’s palsy affecting Case 1.
On days 37–40 she reported mild nasal congestion and discharge,
on day 43 mild cough, and on days 44–45 left sided shoulder/neck
pain ‘‘like a pulled muscle’’, and took diclofenac. On day 44 she
developed left retro-auricular pain, stinging of left eye with
increased tearing, and jaw paresthesia, followed by facial
asymmetry and difficulty closing left eye. A local Emergency
Room diagnosed Bell’s palsy, but gave no treatment. On day 45
abnormal taste sensation developed and she attended the trial site.
There was no history of trauma, headache, fevers, aura/visual
disturbance, or abnormality of smell. She was afebrile; cardiovas-
cular, respiratory, abdominal, ENT examinations normal; no
mastoid tenderness, rashes or peri-auricular vesicles. Normal sense
of smell on testing; cranial nerves 2–6 intact; pupils equal and
responsive, fundoscopy normal. A grade IV left lower motor
neurone facial nerve palsy was present with difficulty distinguish-
ing salt, sour and bitter taste on anterior portion of tongue, and
increased tearing. Hearing and balance, Rinne’s and Weber tests
normal. Gag reflex present but decreased on left. Cranial nerves
11–12 normal, with appearance of tongue deviating to right
(feature of Bell’s palsy due to mouth asymmetry, not twelfth nerve
defect). Sensation over head and neck normal. She was prescribed
prednisolone, omeprazole, aciclovir, eye drops & patches [12].
Grade II weakness was present on day 44, with reduced taste
sensation. A Consultant Neurologist confirmed the diagnosis on
day 48. Palsy almost completely resolved by day 50, and steroids
were discontinued, with complete recovery by day 58. She was
discharged on day 214 with no further relapse.
There were no clinically significant abnormalities of hematology
and biochemistry throughout study. Screening and day 224
samples were tested for: HIV 1&2 antibody, p24 antigen and HIV
nucleic acid PCR (negative); VZV (IgG positive, no rise in titer,
IgM negative); B. burgdorferi (IgG and IgM negative); measles (IgG
positive, no rise in titer); mumps, HSV 1 and 2 (IgG negative);
EBV (EBNA IgG positive, no rise in titer, EBV Early Antigen IgG
and IgM negative); CMV (IgG and IgM negative); ANA, ANCA
(negative). ACE 42 U/L day 27, 24 day 55 (normal range 8–52).
Immune responses to LTK63
LT is a potent mucosal antigen [13] therefore antibody
responses to LTK63 were measured using an in-house ELISA
on serum and nasal lavage samples obtained from subjects before
and after immunization. IgG and IgA responses to LTK63 were
observed after each immunization (Figure 1), and although
numbers in each group are small, responses in cases experiencing
Bell’s palsy were generally comparable with group mean.
Discussion
We report two cases of Bell’s palsy temporally associated with
nasal administration of non-toxic LTK63, possibly a result of
transient interference with peripheral nerve function due to
accumulation of LTK63 molecules, or inflammation arising from
immune response to LTK63, following ganglioside binding and
retrograde neuronal transport; or another unknown mechanism.
Both subjects rapidly recovered without long-term sequelae. The
situation of our subjects prospectively recording the progressive
symptoms and signs of Bell’s palsy from a clearly defined time-
point offered an unique opportunity to study in some detail the
pathophysiology of the neurological disturbance, in contrast with
most clinical studies in which symptoms are recalled retrospec-
tively, and in which there is no clearly defined starting point.
Bell’s palsy arises from facial nerve compression within the facial
canal, or acute demyelination, usually associated with herpes
infection, but also other conditions including parenteral immuni-
zation, infections, tumors and autoimmune diseases [11]. Cholera
toxin (CT) undergoes retrograde axonal transport by binding
neuronal gangliosides [14], a property shared by LT, but unlike
tetanus toxin CT cannot cross synapses [14]. Considerable
attention has focused on safety issues associated with possible
olfactory nerve transport of CT/LT molecules to the CNS [15], a
single cell-system with no synapse outside the CNS. Whereas
human olfactory nerve endings are poorly accessible to passive
instillation of drops into the anterior nares, facial nerve
secretomotor fibers richly supply nasal mucosa, and can transport
molecules to the geniculate ganglion via the nerve of the pterygoid
canal and greater petrosal nerve. The sequential appearance of
classical symptoms and signs of Bell’s palsy, without olfactory
disturbance we observed, are consistent with progressive interfer-
ence of peripheral (not central nervous system) facial nerve
function by a process initiated during retrograde axonal transport.
Intriguingly, secretomotor symptoms preceded both cases, which is
of interest as antecedent symptoms of ‘‘upper respiratory tract
infection’’ are reported in 20% of Bell’s palsies [16], and often
ascribed as a cause rather than a consequence of the neurological
defect. The involvement of trigeminal and glossopharyngeal
nerves in Case 2 is well recognised [16] possibly due to spread
of the causal agent (usually a herpes virus) via superficial greater
petrosal nerve [17], which connects facial, trigeminal and
glossopharyngeal nerves. The migraine-like aura without head-
ache in Case 1 is interesting as carotid plexus autonomic
innervation joins the greater petrosal nerve, and release of
vasoactive neuropeptides from trigeminal and parasympathetic
perivascular fibers has been associated with migraine [18]. The
onset of symptoms on day 44 and 60 (with a possible relapse
31 days after second immunization in Case 1) is consistent with the
highest risk of palsy between 31 to 60 days after NasalFlu [3],
suggesting a common pathogenesis.
An annual Bell’s palsy incidence of 32 per 100,000 was reported
in a European population [10], We observed two cases of Bell’s
palsy in 25 subjects, receiving 59 LTK63 30 mg doses, making a
chance association highly unlikely. Only 13 cases per 10,000 were
estimated within 91 days after vaccination with NasalFlu [3], and
no toxicity was seen during 42 day follow-up in a Phase I trial of a
Chiron (now Novartis) intranasal inactivated influenza vaccine
[19] in which 18 subjects received two doses of 30 mg LTK63
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Figure 1. Serum and nasal lavage antibody response to LTK63. Anti-LTK63 specific IgG and IgA in serum (mg/mL, (A)) and nasal lavage
(ng/mL, (B)) measured by ELISA. Time course for individual response of Case 1 (left figures) and Case 2 (right figures) shown as blue lines. Response of
remainder of group shown as group mean: for Case 1 (closed circles) n = 4; for Case 2 (who received only one dose) n = 15 receiving three doses
(closed circles), and n= 4 receiving one dose (open circles). Error bars indicate SEM. Immunization days 0, 28, and/or 56 indicated by broad ticks
crossing x-axis.
doi:10.1371/journal.pone.0006999.g001
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alone; a further 16 two doses of 30 mg LTK63 with influenza
antigens and particulate biovector; and another 30 receiving two
doses of 3 or 10 mg LTK63 with antigens and biovector. It is
possible that our free suspension of LTK63 allowed more
molecules to bind neuronal gangliosides than when complexed
with virosomes (NasalFlu) or biovectors (Chiron-Novartis vaccine),
and the absence of symptoms in 18 subjects receiving LTK63
alone in the Chiron nasal vaccine trial is not significant (Fisher’s
exact test: p=0.52; Odds Ratio 3.2 (0.15–68).
It was speculated [20] that reactivation of herpes infection may
have been induced by toxicity of the LT used in NasalFlu (which
induced diarrhea when given orally [4]) as extensive preclinical
evaluation, including primates, was unremarkable [21]. We
followed standard UK guidance and both subjects received
antiviral and steroid therapy, and rapidly made a full recovery,
although it is not possible to determine whether the treatment
affected the course of the disease. Both cases were seronegative for
HSV (although Case 1 had some weak serological evidence of
asymptomatic EBV infection in the months prior to recruitment),
and LTK63 is rendered completely non-toxic by an amino acid
substitution in the enzyme active site that abolishes ADP-
ribosylation [2]. Our vaccines were produced under GMP
conditions, free of contaminants including lipopolysaccharide,
and nasal testing in rabbits, including detailed CNS histology,
revealed no localized or generalized toxicity. Extensive preclinical
experience with nasal LTK63 [2] has demonstrated mucosal
adjuvanticity without toxicity, including macaques [6], Guinea
Pigs [22], and mice [5].
In conclusion, the unique anatomical predisposition of the facial
nerve to compression within the facial canal suggests that nasal
administration of neuronal-binding LT-derived molecules is
inadvisable. However, the extensive clinical safety record of oral
[13] and percutaneous [23] administration of CT/LT molecules
provides a rationale for their continued investigation as potent
mucosal and topical vaccine antigens and adjuvants. The lack of
reported facial nerve paralysis following nasal immunization in
subjects not receiving LT adjuvants supports the continued
exploration of nasal delivery as an effective and needle-free route
of immunization against mucosally-acquired infections as influenza
and HIV.
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